. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Hepatology. 2018 Dec 28;71(1):214–224. doi: 10.1002/hep.30085

Table 3.

Performance of PREsTo & Other Prognostic Markers in Derivation & Validation Cohorts

Prognostic Marker	C-statistic (95% CI)
	Derivation Cohort-Secondary Endpoint
PREsTo	0.96 (0.93-0.98)
MELD Score	0.73 (0.63-0.82)
Mayo PSC Risk	0.84 (0.76-0.90)
SAP <1.5 × ULN	0.64 (0.56-0.70)
	Validation Cohort-Secondary Endpoint
PREsTo	0.90 (0.85-0.95)
MELD Score	0.72 (0.57-0.84)
Mayo PSC Risk	0.85 (0.77-0.92)
SAP <1.5 × ULN	0.65 (0.55-0.73)

Abbreviations: PREsTo (PSC risk estimate tool); CI (confidence interval); SAP × ULN (serum alkaline phosphatase × upper limit of normal); PSC (primary sclerosing cholangitis); MELD (model end stage liver disease)